Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6234, AZD9550, and EE/LEVO PK Study in Healthy Females With Overweight or Obesity
NCT07013643Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2025
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of lenbelintide and AZD9550 in obesity (4 arms), sponsored by AstraZeneca. Primary endpoints: Area under the concentration-time curve from time 0 to infinity, Area under the concentration-time curve from time of dosing to the last measurable concentration and 3 more. Started Jun 2025; status: active, not recruiting.
02
Drugs
lenbelintideAZD9550
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07013643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07013643.